ProMIS Neurosciences (PMN) late Wednesday filed a shelf registration statement with US regulators for the potential sale of up to $200 million of securities, to be offered from time to time.

The filing covers common shares, preferred shares, subscription receipts, debt securities, warrants and units.

The company said it intends to use the net proceeds for the clinical development of PMN310 therapeutic candidate, for working capital and general corporate purposes.